Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2009
Anagnostis, P., Karagiannis A., Tziomalos K., Kakafika A. I., Athyros V. G., & Mikhailidis D. P. (2009).  Adrenal incidentaloma: a diagnostic challenge.. Hormones (Athens). 8(3), 163-84.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Anti-inflammatory effects of fibrates: an overview.. Curr Med Chem. 16(6), 676-84.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T., & Athyros V. G. (2009).  Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?. Angiology. 60(4), 397-402.
Pagourelias, E. D., Koumaras C., Kakafika A. I., Tziomalos K., Zorou P. G., Athyros V. G., et al. (2009).  Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. Angiology. 60(1), 74-81.
Anagnostis, P., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.. J Clin Endocrinol Metab. 94(8), 2692-701.
Tziomalos, K., Athyros V. G., & Mikhailidis D. P. (2009).  Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.. Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Karagiannis, A., Hatzitolios A. I., Athyros V. G., Deligianni K., Charalambous C., Papathanakis C., et al. (2009).  Implementation of guidelines for the management of arterial hypertension. The impulsion study.. Open Cardiovasc Med J. 3, 26-34.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  JUPITER: major implications for vascular risk assessment.. Curr Med Res Opin. 25(1), 133-7.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
Tziomalos, K., Athyros V. G., Wierzbicki A. S., & Mikhailidis D. P. (2009).  Lipoprotein a: where are we now?. Curr Opin Cardiol. 24(4), 351-7.
Mitsiou, E. K., Tziomalos K., Anagnostis P., Karagiannis A., & Athyros V. G. (2009).  Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.. Hellenic J Cardiol. 50(6), 445-8.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Tziomalos, K., Kakafika A. I., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  The role of statins for the primary and secondary prevention of coronary heart disease in women.. Curr Pharm Des. 15(10), 1054-62.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Tziomalos, K., Athyros V. G., Karagiannis A., Kolovou G. D., & Mikhailidis D. P. (2009).  Triglycerides and vascular risk: insights from epidemiological data and interventional studies.. Curr Drug Targets. 10(4), 320-7.
2008
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.